Results 181 to 190 of about 5,204,838 (351)

Stopping power ratio databases for proton therapy dose calculation

, 2020
N Pischom, Sawwanee Asavaphatiboon, P Tangboonduangjit, Thiansin Liamsuwan   +3 more
openalex   +1 more source

Allosteric Modulation of Pathological Ataxin‐3 Aggregation: A Path to Spinocerebellar Ataxia Type‐3 Therapies

Advanced Science, EarlyView.
This study uncovers a new allosteric site in the Josephin domain of ataxin‐3 targeted by the molecular tweezer CLR01, which modulates protein aggregation, improves synaptic function in neuronal cells, and delays motor dysfunction in animal models.
Alexandra Silva, Sara Duarte‐Silva, Pedro M. Martins, Beatriz Rodrigues, Débora Serrenho, Daniela Vilasboas‐Campos, Andreia Teixeira‐Castro, Julio Vieyto‐Nuñez, Joel Mieres‐Perez, Francisco Figueiredo, Martyna Podlasiak, Tatiana Van‐der‐Kellen, Joana Fraga, James Noble, Carter Lantz, Niki Sepanj, Daniela Monteiro‐Fernandes, Sara Guerreiro, Andreia Neves‐Carvalho, Joana Pereira‐Sousa, Frank‐Gerrit Klärner, Thomas Schrader, Joseph A. Loo, Annalisa Pastore, Elsa Sanchez‐Garcia, Gal Bitan, Ana Luísa Carvalho, Patrícia Maciel, Sandra Macedo‐Ribeiro   +28 more
wiley   +1 more source

Photon-counting computed tomography for stopping power ratio prediction in proton therapy. [PDF]

Med Phys
Huijskens S, van Straten M, Lopes PC, Rossi L, Wohlfahrt P, Hoogeman M.   +5 more
europepmc   +1 more source

GAMBAS -- Fast Beam Arrangement Selection for Proton Therapy using a Nearest Neighbour Model [PDF]

Renato Bellotti, Nicola Bizzocchi, Antony Lomax, Andreas Adelmann, Damien C. Weber, Jan Hrbáček   +5 more
openalex   +1 more source

Targeting Adipose Tissue Function Protects Against Heart Failure with Preserved Ejection Fraction

Advanced Science, EarlyView.
This study explores the role adipose tissue (AT) phenotypes have in determining cardiovascular outcomes in an obesity‐related heart failure with preserved ejection fraction (HFpEF) model. Pharmacological induction of thermogenesis promoted resilience to HFpEF‐induced remodeling of AT and conferred cardioprotection. Surgical and genetic models confirmed
Jordan Jousma, Zhenbo Han, Jooman Park, Gege Yan, Sen Zhang, Youjeong Kwon, Sarath Babu Nukala, Jindpreet Kandola, Sandra Pinho, Chong Wee Liew, Yuwei Jiang, Sang‐Ging Ong   +11 more
wiley   +1 more source

A novel automated framework for multi-engine Monte Carlo model commissioning in proton therapy. [PDF]

Phys Imaging Radiat Oncol
Pi Y, Wang H, Zhang Y, Peng Z, Zeng X, Guo Y, Liu C.   +6 more
europepmc   +1 more source

Mathematical Modelling for Patient Selection in Proton Therapy

, 2018
T. Mee, N.F. Kirkby, K.J. Kirkby
openalex   +2 more sources

Defining the role of proton therapy in the optimal management of paediatric patients in Australia and New Zealand [PDF]

, 2015
Mary Dwyer
openalex   +1 more source

Modifying Glucose Metabolism Reverses Memory Defects of Alzheimer's Disease Model at Late Stages

Advanced Science, EarlyView.
Using spatial transcriptomics, we show that ferul enanthate (SL‐ZF‐01) reverses episodic‐like memory deficits in aged, but not young, Alzheimer’s disease (AD) mice. SL restores glucose metabolism and Glucose Transporter 1/3 expression via an ‘Aging‐AD‐Rescue’ pattern, rescuing deficits seen in aged AD mice.
Fang Liu, Yiyu‐Li Tang, Zong‐Bo Zhang, Ya‐Hong Tan, Si‐Hui Lin, Ni‐Ya Wang, Jin‐Nan Li, Zhi‐Jie Pan, Jian‐Feng Li, Jing‐Fei Huang, Yu‐Qiang Ding, Chun‐Ming Guo, Lin Xu, Cheng Peng, Qi‐Xin Zhou   +14 more
wiley   +1 more source

Long-Term Outcomes of Consolidative Proton Therapy for Pediatric Classical Hodgkin Lymphoma. [PDF]

Int J Part Ther
Martir-Vargas D, Indelicato DJ, Bechtel A, Bansal M, Milner J, Dean JB, Morris CG, Mendenhall NP, Mailhot Vega RB.   +8 more
europepmc   +1 more source